Fair Value Calculator Fair Value Calculator
EN DE

Suzhou MedicalSystem Technology Co (603990) Fair Value & Analysis

Healthcare · CN · Market cap 6.6B CNY

SM Suzhou MedicalSystem Technology Co 603990 · SHG
Price¥20.25
Fair Value¥2.14
Upside-89.4%
Quality58/100
Watch Suzhou MedicalSystem Technology Co for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ¥1.63 – ¥2.14

Fair value as of: Jul 12, 2026

From 17 valuation models · updated today

Share price −3.6% over the past month.

Price vs Fair Value (12 months)

¥22.96 ¥13.81 Fair Value ¥2.14 Jun 2025 Jul 2026

12‑month range ¥13.81 – ¥22.96 · fair‑value band ¥1.63 – ¥2.14 · the ¥20.25 price screens above the ¥2.14 fair value. As of Jul 12, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Suzhou MedicalSystem Technology Co (603990) currently trades at ¥20.25, while our model-based Fair Value estimate is ¥2.14 — implying the stock looks roughly 89.4% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, Suzhou MedicalSystem Technology Co generated revenue of 300M CNY at a net margin of 6.5%. Revenue declined 2.6% year over year. It earns a return on equity of 2.5%. The balance sheet holds a net cash position of 18.0M CNY. Fundamentals as of Jul 12, 2026

Our scenario range runs from ¥1.63 (bear case) to ¥2.14 (bull case); at ¥20.25, the current price sits above that range. The share trades about 15% below its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside — at -89%, 603990 screens richer than that median.

Key figures & financial health

Revenue (TTM) 300M CNY
Revenue growth (YoY) -2.6%
Net margin 6.5%
Return on equity 2.5%
Free cash flow −3.2M CNY FY2025
P/E ratio 360.0
More key figures
Operating margin 9.9%
EPS (TTM) ¥0.0600
EPS growth (YoY) -87.5%
Net cash 18.0M CNY FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.

About the company

Suzhou MedicalSystem Technology Co., Ltd. provides solutions in clinical informatics and digital hospital field in China. It offers DoCare anesthesia clinical information system that focuses on serving the perioperative clinical work; and provides streamlined, informational, automatic, and intelligent integrated management platform for clinical business. The company also provides DoCare intensive auxiliary diagnosis clinical information system that mines and scientifically analyzes for ICU patients' treatment data with medical information, such as patients' treatment information, inspection information, nursing information, and doctor's advice data. In addition, it offers DoCare operative medical behavior management system that establishes the intelligent management system for the operation resources and personnel behavior; and DoCare emergency clinical information system for management of emergency clinical, including pre-hospital first aid, pre-examination and triage, emergency …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Suzhou MedicalSystem Technology Co reported revenue of ¥300M in FY2025 versus ¥354M in FY2021, a compound −4.1%/yr. Reported net income was ¥39.2M in FY2025, compounding −1.7%/yr from FY2021.

Revenue −4.1%/yr
FY21 ¥354M
FY22 ¥306M
FY23 ¥618M
FY24 ¥464M
FY25 ¥300M
Net income −1.7%/yr
FY21 ¥42.0M
FY22 ¥33.6M
FY23 −¥269M
FY24 −¥279M
FY25 ¥39.2M

Is 603990 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Suzhou MedicalSystem Technology Co Fair Value". https://www.fairvalue-calculator.com/stock/603990

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $153.16 $183.66 +20%
Pro Medicus Limited PME A$165.64 A$28.02 -83%
BrightSpring Health Services, Inc BTSG $57.40 $23.87 -58%
Tempus AI, Inc TEM $48.61 $12.67 -74%
HealthEquity, Inc HQY $84.61 $79.57 -6%
M3, Inc MTHRY $5.20 $5.32 +2%
Hinge Health, Inc HNGE $70.38 $31.17 -56%
Ping An Healthcare and Technology Company PANHF $0.9000 $0.6700 -26%
10x Genomics, Inc TXG $31.04 $20.68 -33%
XtalPi Holdings 2228 HK$7.48 HK$1.03 -86%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Suzhou MedicalSystem Technology Co (603990) undervalued?
As of Jul 12, 2026, our model estimates a fair value of ¥2.14 versus a price of ¥20.25 — about −89% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 603990?
Our model-based fair value for Suzhou MedicalSystem Technology Co is ¥2.14 (as of Jul 12, 2026), built from audited fundamentals. The current price is ¥20.25.
What is the quality score of 603990?
Suzhou MedicalSystem Technology Co has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Suzhou MedicalSystem Technology Co (603990)?
Suzhou MedicalSystem Technology Co reported trailing-twelve-month revenue of about 300M CNY (latest available figure, as of Jul 12, 2026).
What is the net profit margin of 603990?
The net profit margin of Suzhou MedicalSystem Technology Co is about 6.5%, meaning it keeps roughly 6.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

14 days Pro free · no card

Unlock the full Suzhou MedicalSystem Technology Co analysis — and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.